You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
| Title |
Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors ? -- A literature-based meta-analysis
|
|---|---|
| Published in |
Journal of Hematology & Oncology, October 2012
|
| DOI | 10.1186/1756-8722-5-62 |
| Pubmed ID | |
| Authors |
Chongrui Xu, Qing Zhou, Yi-long Wu |
| Abstract |
In the first line treatment of non-small cell lung cancer (NSCLC), several clinical trials have shown that not all NSCLC patients can benefit from treatment with tyrosine kinase inhibitors (TKIs) than receiving chemotherapy. Some trials treated patients with TKI according to their clinical characteristics. A few studies only chose patients with an epidermal growth factor receptor (EGFR) mutation for TKI therapy. We aimed to determine whether patients could be treated with TKIs based on clinical factors in the first-line setting. |
Mendeley readers
The data shown below were compiled from readership statistics for 35 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 3% |
| United States | 1 | 3% |
| Unknown | 33 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 17% |
| Student > Bachelor | 5 | 14% |
| Student > Ph. D. Student | 4 | 11% |
| Other | 3 | 9% |
| Student > Master | 3 | 9% |
| Other | 8 | 23% |
| Unknown | 6 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 37% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 9% |
| Biochemistry, Genetics and Molecular Biology | 3 | 9% |
| Unspecified | 2 | 6% |
| Nursing and Health Professions | 2 | 6% |
| Other | 4 | 11% |
| Unknown | 8 | 23% |